Novome Biotechnologies Stock

Novome Biotechnologies is a biotechnology company focused on engineering defined activities into the human.

Sign up today and learn more about Novome Biotechnologies Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Novome Biotechnologies Stock

Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered Microbial Medicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications.

Funding History

December 2016$225K
January 2017$536K
March 2018$4.5M
August 2018$1.3M
January 2020$33.0M
September 2022$43.5M

Management

Co-Founder

Zachary Russ

Co-Founder & CSO

Will DeLoache

Co-Founder

Liz Shepherd

CEO

Blake Wise

Board Member

Dan Janney

Board Member

Kiersten Stead

Board Observer

Mira Chaurushiya

Board Member

Blake Wise

Board Member

Will DeLoache

CFO

Bill McLeod

Head Of Technical Operations

Tariq Warsi

Co-Founder

Weston Whitaker

Board Member

Andrew Schwab

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo